Doull v. Foster

CourtMassachusetts Supreme Judicial Court
DecidedFebruary 26, 2021
DocketSJC 12921
StatusPublished

This text of Doull v. Foster (Doull v. Foster) is published on Counsel Stack Legal Research, covering Massachusetts Supreme Judicial Court primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Doull v. Foster, (Mass. 2021).

Opinion

NOTICE: All slip opinions and orders are subject to formal revision and are superseded by the advance sheets and bound volumes of the Official Reports. If you find a typographical error or other formal error, please notify the Reporter of Decisions, Supreme Judicial Court, John Adams Courthouse, 1 Pemberton Square, Suite 2500, Boston, MA, 02108-1750; (617) 557- 1030; SJCReporter@sjc.state.ma.us

SJC-12921

SETH DOULL1 & another2 vs. ANNA C. FOSTER & another.3

Franklin. October 5, 2020. - February 26, 2021.

Present: Budd, C.J., Gaziano, Lowy, Cypher, & Kafker, JJ.

Negligence, Medical malpractice, Causation, Standard of care. Medical Malpractice, Standard of care, Consent to medical treatment. Practice, Civil, Instructions to jury, Amendment of complaint, Interrogation of jurors.

Civil action commenced in the Superior Court Department on May 28, 2014.

The case was tried before Mary-Lou Rup, J., and a motion for a new trial was considered by her.

The Supreme Judicial Court on its own initiative transferred the case from the Appeals Court.

Krzysztof G. Sobczak for the plaintiffs. Tory A. Weigand for the defendants. Jennifer A. Creedon & Stephanie M. Gazda, for Massachusetts Defense Lawyers Association, amicus curiae, submitted a brief.

1 Individually, as personal representative of the estate of Laura Doull, and as next friend of Troy Doull.

2 Megan Doull. 3 Robert J. Miller. 2

Brendan G. Carney, Thomas R. Murphy, Kevin J. Powers, & Elizabeth N. Mulvey, for Massachusetts Academy of Trial Attorneys, amicus curiae, submitted a brief.

KAFKER, J. Causation has been a continually contested

concept in tort law, confounding courts, commentators, and

practitioners. In this medical malpractice case, we are asked

once again to clarify our case law on causation, along with a

series of other issues that are more readily decided.

Specifically, we examine the use of two competing causation

standards: the traditional but-for causation standard and the

alternative substantial contributing factor standard. After

careful review, we conclude that the traditional but-for factual

causation standard is the appropriate standard to be employed in

most cases, including those involving multiple alleged causes.

This is the approach recommended by the Restatement (Third) of

Torts: Liability for Physical and Emotional Harm (2010)

(Restatement [Third]). In doing so, we conclude that the

substantial factor test is unnecessarily confusing and

discontinue its use, even in multiple sufficient cause cases.

Because the jury in this case were instructed using traditional

but-for causation principles, the instructions were proper. We 3

also reject all of the plaintiffs' other claims on appeal and

affirm the order denying a new trial.4

1. Background. We summarize the facts that could have

been found by the jury, reserving certain facts for later

discussion.

a. Facts. Between 2008 and 2011, Laura Doull was a

patient of Anna C. Foster, a nurse practitioner, and her

supervisor, Dr. Richard J. Miller (collectively, the

defendants). Miller, an internist, owned the medical practice

where Doull was a patient.

In August 2008, Doull had an appointment with Foster to

seek advice regarding perimenopause-related symptoms. Foster

prescribed Doull a topically applied, naturally derived

progesterone cream to treat the symptoms.5 Foster admitted that

she did not document any conversation that she had with Doull

about the risks and benefits of, or the alternatives to, the

progesterone cream, but she did testify that they discussed

alternatives to it. However, Foster stated that she did not

4 We acknowledge the amicus briefs submitted by the Massachusetts Academy of Trial Attorneys and the Massachusetts Defense Lawyers Association. 5 Progesterone is a hormone that humans naturally produce. Supplementing the progesterone that the human body produces is a form of hormone replacement therapy typically used to treat menopause- or perimenopause-related symptoms. Progesterone supplements come in both synthetic and naturally derived forms. 4

discuss the possibility with Doull that the progesterone cream

could cause blood clots because she did not consider this to be

a risk. Doull continued to use the progesterone cream through

the spring of 2011.

Earlier that spring, Doull had visited Miller's practice on

three separate occasions to complain about shortness of breath.

Doull met with Foster on each visit, and Foster performed a

physical examination of Doull each time. Doull had a history of

asthma and allergies. At the spring 2011 visits, Foster

diagnosed Doull's shortness of breath as a symptom of some

combination of these long-standing conditions. Miller did not

examine Doull during any of these visits.

In May 2011, Doull had a "seizure-like event" and was

transported to the hospital. At the hospital, she was diagnosed

with a pulmonary embolism, a condition where blood clots or

other substances block portions of the pulmonary arteries in the

lungs. A pulmonary embolism may cause shortness of breath as

well as chronic thromboembolic pulmonary hypertension (CTEPH), a

rare disease where pressure in the pulmonary artery increases

and causes the heart to fail. Indeed, that May, Doull was

diagnosed with CTEPH. A lung scan revealed that blood clots in

Doull's lungs were chronic.

In November 2011, Doull underwent surgery in an attempt to

remove the blockage from her lungs, but the procedure proved 5

unsuccessful. After the surgery, Doull was prescribed various

medications to treat the pulmonary hypertension that had

resulted from her CTEPH. None of these medications abated the

disease. In 2015, Doull died from complications arising from

CTEPH. She was forty-three years old.

b. Procedural history. Prior to her death, Doull and

various family members (collectively, the plaintiffs) commenced

this suit against the defendants, claiming negligence, failure

to obtain informed consent, and loss of consortium.6 Four months

before trial, the plaintiffs moved to amend their complaint to

include the manufacturer of the progesterone cream, Women's

International Compounding Inc. (WIC), as a defendant. The trial

judge denied the plaintiffs' motion.

At trial, the plaintiffs argued that Miller and Foster

failed to obtain informed consent from Doull concerning the

progesterone cream's risks and alternatives, that Foster failed

to diagnose Doull's pulmonary embolism during the spring 2011

visits, and that Miller failed to supervise Foster adequately

during all relevant times.

To support these claims, Dr. Paul Genecin, a primary care

internal medicine physician and the plaintiffs' expert witness,

testified that natural progesterone was not any safer than

6 Doull's estate continued to prosecute the claims after her death, amending the complaint to add a wrongful death claim. 6

synthetic derivations of the hormone, and that the cream likely

caused Doull to develop blood clots. Genecin also testified

that Foster had failed to investigate adequately Doull's

shortness of breath complaints during the spring 2011 visits.

He testified that diagnosis of Doull's pulmonary embolism during

the spring of 2011 could have prevented the onset of CTEPH, and

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Price Waterhouse v. Hopkins
490 U.S. 228 (Supreme Court, 1989)
June v. Union Carbide Corp.
577 F.3d 1234 (Tenth Circuit, 2009)
Mitchell v. Gonzales
819 P.2d 872 (California Supreme Court, 1991)
Thompson v. Kaczinski
774 N.W.2d 829 (Supreme Court of Iowa, 2009)
Tritsch v. Boston Edison Co.
293 N.E.2d 264 (Massachusetts Supreme Judicial Court, 1973)
O'CONNOR v. Raymark Industries, Inc.
518 N.E.2d 510 (Massachusetts Supreme Judicial Court, 1988)
Collins v. Baron
467 N.E.2d 171 (Massachusetts Supreme Judicial Court, 1984)
Allen v. Batchelder
459 N.E.2d 129 (Massachusetts Appeals Court, 1984)
Mathis v. Massachusetts Electric Co.
565 N.E.2d 1180 (Massachusetts Supreme Judicial Court, 1991)
Welch v. Keene Corp.
575 N.E.2d 766 (Massachusetts Appeals Court, 1991)
Avery v. Steele
608 N.E.2d 1014 (Massachusetts Supreme Judicial Court, 1993)
Boothby v. Texon, Inc.
608 N.E.2d 1028 (Massachusetts Supreme Judicial Court, 1993)
Michnik-Zilberman v. Gordon's Liquor, Inc.
453 N.E.2d 430 (Massachusetts Supreme Judicial Court, 1983)
Bernier v. Boston Edison Co.
403 N.E.2d 391 (Massachusetts Supreme Judicial Court, 1980)
Castellucci v. United States Fidelity and Guaranty Co.
361 N.E.2d 1264 (Massachusetts Supreme Judicial Court, 1977)
Mullins v. Pine Manor College
449 N.E.2d 331 (Massachusetts Supreme Judicial Court, 1983)
Franklin v. Albert
411 N.E.2d 458 (Massachusetts Supreme Judicial Court, 1980)
Falvey v. Hamelburg
198 N.E.2d 400 (Massachusetts Supreme Judicial Court, 1964)
Pfeiffer v. Salas
271 N.E.2d 750 (Massachusetts Supreme Judicial Court, 1971)
Callahan v. Cardinal Glennon Hospital
863 S.W.2d 852 (Supreme Court of Missouri, 1993)

Cite This Page — Counsel Stack

Bluebook (online)
Doull v. Foster, Counsel Stack Legal Research, https://law.counselstack.com/opinion/doull-v-foster-mass-2021.